tiprankstipranks
Advertisement
Advertisement

INBX Stock Latest News

Inhibrx Biosciences Expands Credit Facility to $500 Million
Company AnnouncementsInhibrx Biosciences Expands Credit Facility to $500 Million
4d ago
8K
INBX
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
14d ago
CTMX
EXEL
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
PremiumCompany Announcements
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
1M ago
8K
INBX
Inhibrx announces FDA acceptance of BLA for ozekibart
PremiumThe Fly
Inhibrx announces FDA acceptance of BLA for ozekibart
1M ago
INBX
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
PremiumCompany Announcements
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
2M ago
8K
INBX
Inhibrx price target raised to $325 from $300 at Stifel
PremiumThe FlyInhibrx price target raised to $325 from $300 at Stifel
2M ago
INBX
Inhibrx reports Q1 EPS ($2.15) vs. ($2.80) last year
Premium
The Fly
Inhibrx reports Q1 EPS ($2.15) vs. ($2.80) last year
2M ago
INBX
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
Premium
Company Announcements
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
2M ago
8K
INBX
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
PremiumThe Fly
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
2M ago
INBX
Inhibrx initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Inhibrx initiated with an Outperform at LifeSci Capital
3M ago
INBX
Inhibrx price target raised to $300 from $150 at Stifel
PremiumThe Fly
Inhibrx price target raised to $300 from $150 at Stifel
3M ago
INBX
Midday Fly By: Boeing, AT&T report Q1 beats
PremiumThe Fly
Midday Fly By: Boeing, AT&T report Q1 beats
3M ago
T
BA
Inhibrx trading halted, volatility trading pause
PremiumThe FlyInhibrx trading halted, volatility trading pause
3M ago
INBX
Inhibrx trading resumes
Premium
The Fly
Inhibrx trading resumes
3M ago
INBX
Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says
Premium
The Fly
Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says
3M ago
MRK
INBX
Inhibrx up 39% at $117 after report of interest from Merck in cancer assets
PremiumThe Fly
Inhibrx up 39% at $117 after report of interest from Merck in cancer assets
3M ago
INBX
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
PremiumCompany Announcements
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
3M ago
8K
INBX
Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart
PremiumThe Fly
Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart
3M ago
INBX
Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls
3M ago
DE
GD
Inhibrx initiated with a Buy at Stifel
PremiumThe FlyInhibrx initiated with a Buy at Stifel
3M ago
INBX
Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year
Premium
The Fly
Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year
4M ago
INBX
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
Premium
Company Announcements
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
5M ago
8K
INBX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >